Link to this page
Biological and Environmental Research Ontology
Last uploaded:
December 23, 2022
| Id | http://purl.obolibrary.org/obo/NCIT_C1372
http://purl.obolibrary.org/obo/NCIT_C1372
|
|---|---|
| Preferred Name | Fostriecin |
| Definitions |
An anti-tumor antibiotic isolated from the bacterium Streptomyces pulveraceus. Fostriecin inhibits topoisomerase II catalytic activity, resulting in impaired DNA and RNA synthesis in various malignant cell types. This agent also inhibits serine/threonine protein phosphatase type 2A in some tumor cell types, thereby interfering with cellular proliferation and differentiation. (NCI04)
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| definition | An anti-tumor antibiotic isolated from the bacterium Streptomyces pulveraceus. Fostriecin inhibits topoisomerase II catalytic activity, resulting in impaired DNA and RNA synthesis in various malignant cell types. This agent also inhibits serine/threonine protein phosphatase type 2A in some tumor cell types, thereby interfering with cellular proliferation and differentiation. (NCI04) |
|---|---|
| prefLabel | Fostriecin
|
| label | Fostriecin
|
| PDQ_Closed_Trial_Search_ID | 41703
|
| code | C1372
|
| prefixIRI | NCIT:C1372
|
| in_subset | |
| Preferred_Name | Fostriecin
|
| FDA_UNII_Code | ZO1648L551
|
| Contributing_Source | FDA
|
| Chemical_Formula | C19H27O9P
|
| Maps_To | Fostriecin
|
| CAS_Registry | 87810-56-8
|
| NSC Number | 339638
|
| NCI_Drug_Dictionary_ID | 41703
|
| Legacy Concept Name | Fostriecin
|
| type | |
| Is_Value_For_GDC_Property | |
| subClassOf | |
| PDQ_Open_Trial_Search_ID | 41703
|
| Semantic_Type |
Organic Chemical
Pharmacologic Substance
Antibiotic
|
| UMLS_CUI | C0118175
|
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |